Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who developed evidence of an autoimmune enteropathy shortly after initiating lenalidomide based therapy.
Keywords: chemotherapy; oncology; pharmacology; plasma cell neoplasms.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.